Completed PHASE2 INTERVENTIONAL 4-arm NCT01060878

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) (CONFIDENT-PD)

Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks

Sponsor: Phytopharm

Conditions Parkinson's Disease

Interventions PYM50028 Placebo

Updated 7 times since 2017 Last updated: Mar 1, 2013 Started: Nov 30, 2010 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Parkinson's Disease and is currently completed. Phytopharm leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Phytopharm

Data source: Phytopharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Bayern, Germany , Beelitz-Heilstätten, Germany , Belgrade, Serbia , Berlin, Germany , Boca Raton, United States , Bochum, Germany , Boise, United States , Bonn, Germany and 88 more locations